Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced plans to release its third quarter 2024 financial and operating results before market open on Tuesday, November 12, 2024. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results. Investors can access the webcast in listen-only mode, with registration recommended 10 minutes before the event.
Neuronetics (NASDAQ: STIM), un'azienda di tecnologia medicale specializzata nel trattamento dei disturbi neuro-sanitari, ha annunciato piani per pubblicare i suoi risultati finanziari e operativi del terzo trimestre 2024 prima dell'apertura del mercato martedì 12 novembre 2024. L'azienda ospiterà una conference call alle 8:30 ora orientale dello stesso giorno per discutere i risultati. Gli investitori possono accedere al webcast in modalità solo ascolto, con registrazione consigliata 10 minuti prima dell'evento.
Neuronetics (NASDAQ: STIM), una empresa de tecnología médica especializada en soluciones para el tratamiento de trastornos neuro-salud, ha anunciado planes para publicar sus resultados financieros y operativos del tercer trimestre de 2024 antes de la apertura del mercado el martes 12 de noviembre de 2024. La empresa llevará a cabo una conferencia telefónica a las 8:30 a.m. Hora del Este el mismo día para discutir los resultados. Los inversores pueden acceder al webcast en modo solo escucha, con registro recomendado 10 minutos antes del evento.
Neuronetics (NASDAQ: STIM), 신경 건강 장애 치료 솔루션을 전문으로 하는 의료 기술 회사,가 2024년 3분기 재무 및 운영 결과를 2024년 11월 12일 화요일 시장 개장 전에 발표할 계획을 발표했습니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 결과를 논의하기 위해 콘퍼런스 콜을 진행할 것입니다. 투자자들은 이벤트 10분 전에 등록하는 것이 권장되는 단독 청취 모드로 웹캐스트에 접근할 수 있습니다.
Neuronetics (NASDAQ: STIM), une entreprise de technologie médicale spécialisée dans les solutions de traitement des troubles neuro-sanitaires, a annoncé des projets de publication de ses résultats financiers et opérationnels du troisième trimestre 2024 avant l'ouverture des marchés le mardi 12 novembre 2024. L'entreprise organisera une conférence téléphonique à 8h30, heure de l'Est, le même jour pour discuter des résultats. Les investisseurs peuvent accéder au webcast en mode écoute uniquement, avec une inscription recommandée 10 minutes avant l'événement.
Neuronetics (NASDAQ: STIM), ein Medizintechnikunternehmen, das sich auf Behandlungsansätze für neurovaskuläre Erkrankungen spezialisiert hat, hat Pläne angekündigt, seine Finanz- und Betriebsergebnisse für das dritte Quartal 2024 vor der Markteröffnung am Dienstag, dem 12. November 2024, zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können auf das Webcast im Nur-Anhör-Modus zugreifen, wobei eine Anmeldung 10 Minuten vor der Veranstaltung empfohlen wird.
- None.
- None.
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/yk5bidgv. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.6 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When will Neuronetics (STIM) release Q3 2024 earnings?
What time is Neuronetics (STIM) Q3 2024 earnings call?
How can I listen to Neuronetics (STIM) Q3 2024 earnings call?
